Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.

Journal of cellular and molecular medicine - 1 Feb 2013

Gäbler Karoline, Rolvering Catherine, Kaczor Jakub, Eulenfeld René, Méndez Sergio Álvarez, Berchem Guy, Palissot Valérie, Behrmann Iris, Haan Claude

Abstract excerpt

The Janus kinase 2 mutant V617F occurs with high frequency in myeloproliferative neoplasms. Further mutations affecting the Janus kinase family have been discovered mostly in leukaemias and in myeloproliferative neoplasms. Owing to their involvement in neoplasia, inflammatory diseases and in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinases
Share to Carbazoles
Share to Cell Cycle

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colony-Forming Units Assay

Share to Flow Cytometry

Share to Furans

Share to Janus Kinase 2

Share to Leukemia, Erythroblastic, Acute

Source

Open in PubMed Open full text

Identifiers

PMID: 23301855
DOI: 10.1111/jcmm.12005
PMCID: PMC3822589

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23301855-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.PMID 23301855Read ↗

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.Semantic proximity Read ↗

The many faces of Janus kinase.Semantic proximity Read ↗

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.Semantic proximity Read ↗

Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.Semantic proximity Read ↗

[Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].Semantic proximity Read ↗

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignanciesSemantic proximity Read ↗

Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations.Semantic proximity Read ↗

Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 InhibitorsSemantic proximity Read ↗

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.Semantic proximity Read ↗

Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity.Semantic proximity Read ↗

Identification of 8-Hydroxyquinoline Derivatives Active Against Somatic V658F Mutant JAK1-Dependent Cells.Semantic proximity Read ↗

Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.